The Cell and Gene Therapy Catapult (CGT Catapult) today announces the appointment of Dr. Ian Campbell to its Board of non-executive Directors representing Innovate UK. Dr. Campbell’s unique experience and industry insight will help shape the future direction of CGT Catapult as it helps expand the UK’s cell and gene therapy landscape.
Dr. Campbell has recently been appointed Chief Business Officer at LifeArc, where he is leading the research charity’s business and development partnerships to translate life science innovation into tangible benefits for patients. His wealth of executive experience in the health and life sciences sector totals more than 15 years with invaluable expertise gained while holding the role of Innovate UK’s (IUK) Interim Chair.
Prior to this, he served as Director for IUK’s Ageing Society, Health and Nutrition initiative. Before his time at IUK, Dr. Campbell was CEO for Arquer Diagnostics, a Sunderland-based company that is leading the way for non-invasive cancer testing.
I am delighted to welcome Ian to our Board. His experience in the industry, and with IUK, gives him a deep understanding of our industry’s needs. The Board and I look forward to working with him as we continue the deliver the Cell and Gene Therapy Catapult’s mission.
It is a pleasure to be joining the CGT Catapult at such an exciting time in the development of the Catapult Network and its wider contribution to the development, manufacturing and clinical adoption of advanced therapies. Having seen the significant impact that the CGT Catapult has had on the UK's advanced therapy sector over recent years, I look forward to contributing to its continued success.